BPI21-004: A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States

View More View Less
  • 1 University of Washington; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA
  • 2 PRECISIONheor, New York, NY
  • 3 EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts; an affiliate of Merck KGaA, Darmstadt, Germany
  • 4 Pfizer Inc, New York, NY
  • 5 EMD Serono, Inc., Rockland, MA, USA; an affiliate of Merck KGaA, Darmstadt, Germany
Restricted access

Corresponding Author: Murtuza Bharmal, PhD
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 213 213 90
PDF Downloads 184 184 60
EPUB Downloads 0 0 0